Globalization and Innovation will drive growth

Transcription

1 JPMorgan Healthcare Conference The New Takeda January 10, 2012 Yasuchika Hasegawa President & CEO 0 Globalization and will drive growth Leading worldwide pharmaceutical company operating in 70 countries Largest Japanese pharmaceutical company Strong financial position 1,540 billion JPY in net revenue, 430 billion JPY in EBITDA expected in FY2011 Strong growth fueled by world-class established product line Innovative pipeline focused on metabolic, oncology, CNS and immunology/inflammatory Potential blockbuster pipeline from internal R&D Successful partnering, acquisition and licensing Transformative vision for New Takeda based on bold strategic initiatives Globalization Growth Culture/ Diversity 1 1

2 Globalization through Expanded Footprint 2 Globalization Key Imperatives for each region Japan Maximize value through high-impact, high productivity marketing organization US EU Emerging Countries Product mix shift to include specialty products Strengthen country presence Focus on emerging markets through appropriate portfolios Invest aggressively in existing and new products Seek alliances with local partners 3 2

3 Globalization Legacy Nycomed Strengths will enhance Takeda s success Strong business momentum/growth in emerging countries e.g. Russia/CIS, Brazil and China Low cost / Multiple products Net Revenue* (Apr-Sep, 2010): 1,404MM Net Revenue* (Apr-Sep, 2011): 1,454MM Emerging Markets 40% Others 11% Developed Countries 49% 3.6% Increase in Net Revenue* 16.6% Increase in Net Revenue in Emerging Markets Emerging Markets 45% Others 9% *Excludes extraordinary factors (Income from selling out Imaging Business in 1H FY2011) Re-stated at FY2011 2H Plan rate to exclude the effect of exchange rates Developed Countries 46% 4 Globalization Nycomed Acquisition Key growth drivers: Russia-CIS market leader and expected synergies Today Nycomed is among the leaders in all CIS Markets (11 countries) Market share in Russia is 3.2% in value ranked at #8 Nycomed is the fastest growing corporation in Top 10 companies by value Nycomed has outperformed the market in Jan-Jun % 21.1% Total market Nycomed (RUB) Launch high potential Takeda products ASAP CV/Metabolic (EDARBI, NESINA) Oncology (ADCETRIS, MEPACT, LEUPLIN) CNS (ROZEREM, LATUDA) Renal (Peginesatide) Historical Sales of Nycomed Russia CIS In-licensed products Nycomed s own products % 52 % 5 3

4 Globalization Benefit of Nycomed Acquisition Leverage Nycomed s emerging markets strength to drive growth Remarkably improves Takeda s performance in EMG by adding Nycomed s high growth momentum Realizes top line synergies for Takeda s products / pipeline through Nycomed s + commercial infrastructure in EMG Legacy Nycomed Takeda 2010 Sales: 1,426 1,248 ( 100MM) Takeda Takeda and Nycomed Note: Sales consists of local subsidiaries excluding licensee revenues Continuous through R&D 7 4

5 - Current Portfolio- Drive Further Growth of Existing Key Products VELCADE (bortezomib): Sustained overall survival advantage (5-year follow-up) to label in patients with previously untreated Multiple Myeloma Data presented at ASH 2011 Subcutaneous formulation (PDUFA: January 23, 2012); Efficacy consistent with IV formulation and the benefit of reduced peripheral neuropathy VECTIBIX (panitumumab): Further penetration of earlier line-setting usage for metastatic colorectal carcinoma (mcrc) (Japan only) NESINA (alogliptin): Highly selective DPP-4 inhibitor for diabetes, the first to satisfy the FDA s cardiovascular safety requirements (PDUFA: April 25, 2012) 8 Focus on R&D Productivity Invigorate discovery Motivate scientists Assume accountability for POC&C* Leverage Takeda s Chemistry and IND Engines Fill the gap in the mid-stage pipeline Maximize and deliver the late stage pipeline Properly Value and Maximize our assets Aggressively Properly value and in-license Aggressive assets In-licensing maximize our assets Develop Vaccine Business Flawlessly execute development programs *Proof of Concept & Competitiveness 9 5

6 Pipeline of Growth-Drivers FY11 FY12 FY13 FY14- FY15 NESINA* DPP-4 inhibitor Higher selectivity *Japanese trade name ADCETRIS* Antibody-drug conjugate Hematological cancer *EU trade name Lu AA21004 Multimodal anti-depressants Mood and anxiety disorders TAK-875 GPR40 agonist Diabetes VELCADE (SQ) The only proteasome inhibitor currently approved Peginesatide Synthetic ESA Once monthly CKD-related anemia TAK , 20 lyase inhibitor Non-steroidal potential Prostate cancer MLN0002 Humanized antibody Selectively binding to α4β7 integrin EDARBI / EDARBYCLOR* Angiotensin II receptor blocker Stronger efficacy *US trade name DEXILANT* Proton pump inhibitor Dual Delayed Release TM *US trade name MLN nd generation proteasome inhibitor(pi) First oral PI DAXAS* PDE4 inhibitor First in class for COPD *EU trade name TAK-438 P-CAB Better efficacy LATUDA* Regional specific products Atypical antipsychotic *EU trade name (TBD) 10 Planned Launches from Promising Pipeline - 1 Peginesatide (US filed; PDUFA on March 27, 2012; EU Phase 3) Synthetic, peptide-based erythropoiesis-stimulating agent for Chronic Kidney Disease related anemia First once-monthly ESA in the U.S. Clean profile vs EPO-associated Pure Red Cell Aplasia ADCETRIS TM * (EU filed, Japan Phase 1/2 ) Antibody-drug conjugate comprising an anti- CD30 monoclonal antibody linked to monomethyl auristatin E New treatment paradigm to satisfy unmet need in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma *In-licensed from Seattle Genetics 11 6

7 Change in HbA1c (%) Planned Launches from Promising Pipeline - 2 TAK-700 (US Phase 3, EU Phase 3, Japan Phase 1) Oral 17, 20 lyase inhibitor for prostate cancer Fast follower with best-in-class potential May allow dosing without prednisone MLN9708 (US Phase 1/2 Completed) First oral proteasome inhibitor in clinical development Evidence for improved tissue distribution in animal models relative to bortezomib Potential in a broad range of hematological and solid tumors 12 TAK-875 (US Phase 3, EU Phase 3, Japan Phase 3) First in class GPR40 agonist for diabetes Reduces glucose levels without the risk of hypoglycemia Initiated trials to assess concomitant use with anti-diabetic drugs including DPP-4 inhibitor 13 Planned Launches from Promising Pipeline P-2 results in US/EU Placebo TAK mg TAK mg TAK mg TAK mg TAK mg Glimepiride 4 mg 0 *# * * * * * * p<0.05 vs placebo # p<0.05 vs Glimepiride All doses significantly reduced A1c Most doses reduced A1c comparable to SU All doses had a markedly lower incidence of hypoglycemia compared with SU (TAK %, SU 16.1%) 7

8 and Globalization The New Takeda Superior Growth through Leading in Medicine Deliver innovation to prevent, treat and ultimately cure diseases with high unmet medical needs Market products around the world Global footprint via Nycomed acquisition Continue to drive the development of appropriate product portfolios Address regional unmet medical needs Global expansion of vaccine business, especially in EMG Employer of choice for top talent Governed by the spirit of Takeda-ism Integrity shown through honesty, fairness and perseverance 14 For Sustainable Growth toward FY2015 Takeda and Nycomed combined performance and synergies will drive sustained growth toward FY2015 Top line synergy and maximization of Takeda s product and pipeline value Achieve annualized 30 billion JPY of cost synergies in FY2014 Consistent dividend per share of 180 JPY during FY FY mid-range plan will be announced in May

9 Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forwardlooking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies. We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise. 9